Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.
| Revenue (Most Recent Fiscal Year) | $15.65M |
| Net Income (Most Recent Fiscal Year) | $-0.37M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 27.40 |
| Pre-Tax Margin (Trailing 12 Months) | -62.89% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -53.17% |
| Return on Assets (Trailing 12 Months) | -36.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.72 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-4.41 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.23 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.88 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 5.38M |
| Free Float | 5.30M |
| Market Capitalization | $22.96M |
| Average Volume (Last 20 Days) | 0.13M |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |